Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

YPN-005

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

KT&G Corp

Drug class:

CDK7 inhibitor

Related drugs:

MYC amplification	Triple Negative Breast Cancer	MYC amplification	Triple Negative Breast Cancer	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D
MYC amplification	Hepatocellular Cancer	MYC amplification	Hepatocellular Cancer	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D
MYC amplification	Estrogen Receptor Positive Breast Cancer	MYC amplification	Estrogen Receptor Positive Breast Cancer	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D
MYC amplification	Pancreatic Cancer	MYC amplification	Pancreatic Cancer	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D
MYC amplification	Prostate Cancer	MYC amplification	Prostate Cancer	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D
MYC amplification	Small Cell Lung Cancer	MYC amplification	Small Cell Lung Cancer	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D
MYC amplification	Ovarian Cancer	MYC amplification	Ovarian Cancer	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D